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Abstract: 
Aims. Atrial fibrillation (AF) transcatheter ablation is a safe and effective procedure. However, 
outcome over 10 years of follow-up has never been reported. The aim of this study is to assess 
outcome, describe predictors of recurrences, and report on quality of life the decade after an AF 
ablation. 
Methods. Patients referred for AF ablation in a single high volume centre from June 2004 to June 
2006 were enrolled and followed in a prospective fashion by yearly clinical assessment and Holter 
monitoring. 
Results. Among 255 patients (42.7% paroxysmal AF, 77% males, after a follow-up of 125±7 
months, 132 (52%) were arrhythmia-free including (58, 32% after a single procedure) while 27 
(10%) progressed to permanent AF. At multivariate analysis, a greater left atrium antero-posterior 
diameter (HR 1.05 95% CI 1.02-1.09, p=0.02) related to arrhythmic  recurrences, while no increase 
in blood pressure (HR 0.06 95% CI 0.02-0.20, p=0.01), BMI (HR 0.06 95% CI 0.02-0.09,  p<0.001) 
and fasting glucose (HR 0.58 95% CI 0.36-0.92, p=0.02) during follow-up were protective for 
arrhythmic recurrences. Overall quality of life improved significantly, significantly related to 
absence of recurrences, arrhythmic burden reduction  and  blood pressure and BMI control 
(p<0.001). 
Conclusion. The outcome of AF ablation over more than 10 years is characterized by a low 
incidence of progression towards permanent AF. Greater LA anteroposterior diameter related to 
arrhythmic recurrences, while blood pressure, BMI and fasting blood glucose control emerged as 
predictors of  sinus rhythm maintenance. Eventually, quality of life improved significantly over the 
follow-up. 
Abstract word count: 245 
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Introduction 
Atrial fibrillation (AF) is the most common supraventricular arrhythmia and its prevalence is 
expected to further increase with progressive ageing of the general population. Due to the 
unsatisfactory efficacy rate and potential adverse effects of antiarrhythmic drugs, AF transcatheter 
ablation (AFTCA) is at present the most effective rhythm control strategy in this population, and 
can be proposed as first-line treatment in selected patients (1). Many data have been previously 
published, even in very large case samples, reporting the efficacy and safety of different 
percutaneous approaches for AFTCA (2). Several studies are available on short and mid-term data 
(3-6). However, prolonging follow-up duration, datasets become increasingly smaller and only 
few data are available about focusing in particular on paroxysmal AF patients (7). To the best of 
our knowledge, few data are available reporting over 10-years outcome analysis for paroxysmal 
and no data for persistent AF patients (including a quality of life analysis) of a large group of 
patients undergone to AF ablation. The aim of the present study is to report the over 10-years 
follow-up in a large cohort of patients (both paroxysmal and persistent AF) undergoing AFTCA in 
a single high volume centre followed on a yearly basis with clinical assessment and holter 
monitoring, focusing on safety, efficacy and predictors of very long-term recurrences and their 
impact on long term quality of life. 
  
 
Methods 
Consecutive patients referred to our Center between June 2004 and June 2006 for AFTCA have 
been included in this retrospective study. All patients signed informed consent before undergoing 
the procedure and to be clinically followed thereafter. Clinical features of the population, 
periprocedural details and follow-up data have been routinely collected and prospectively included 
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in a registry. Procedures were performed by three experienced physicians in a single high volume 
Center. In order to avoid unknown confounding factors impacting AF recurrence rates, patients 
with hypertrophic or moderate-to-severe valvular disease (n=76) were excluded. 
 
Ablation procedure  
Procedural details have been reported elsewhere (8). Briefly, following June 2004 the ablation 
technique was standardized as follows: AFTCA approach encompassed antral pulmonary veins 
isolation (PVI) in all cases of paroxysmal AF. Additional linear lesions (roof line and mitral 
isthmus line, performed anteriorly or posteriorly according to the presence of fragmented 
potentials), validated by the appropriate pacing manoeuvers and/or activation mapping (9) and/or 
ablation of complex fractionated atrial electrograms (10), defined as electrograms with >2 distinct 
peaks and duration longer than 70 msec, were performed in persistent/long-standing AF, in 
patients with cardiomyopathies and in case of redo procedure. The choice to perform only linear 
ablation or additional CFAE ablation was based on substrate mapping: in case of large areas of 
fragmentation in the left atrium, CFAE ablation was performed on top of PVI + roof and left 
isthmus line. 
 
Follow up 
Recurrences were detected by routine ambulatory visits (performed at 1, 3, 6 months and then 
twice a year), with collection of patients’ characteristics, blood samples, symptoms and 24 hours 
Holter ECG recordings. Rhythm or rate control strategy was registered according to the referring 
physician’s advice, as for the antiarrhythmic drugs prescribed. Arrhythmic recurrences were 
defined as the presence of ECG-documented sustained AF, atypical flutter or atrial tachycardia 
lasting more than 30 seconds.  
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Based on the routinely collected patients’ characteristics (e.g. arterial pressure and BMI) and blood 
samples, patients were classified as within the “no increase” group in case the parameter did not 
worsen at consecutive ambulatory visits over time. 
 
Statistical analysis  
Categorical variables are reported as counts and percentages, while continuous variables as median 
and interquartile range (IQR). Correlations between baseline characteristics and AF recurrences 
were tested in cross tabulation tables by means of the Pearson Chi-Square or Fisher’s Exact Test 
and by one-way ANOVA, respectively for categorical and continuous variables. To test the 
independent correlation of these parameters with AF recurrences, all variables reporting a 
significant correlation at univariate analysis were included in a stepwise multivariate Cox 
regression model. Kaplan Meier curves were used to measure AF recurrence-free survival over 
time, stratified by the presence of underlying cardiomyopathy or not and compared by log-rank 
test. A two-sided p-value <0.05 was considered statistically significant. Additionally, cluster 
analysis on quality of life was performed using the two-step clustering procedure as suggested in 
literature. In the first step, a hierarchical cluster analysis was conducted using Ward’s method on 
squared Euclidian distances. We examined the plausibility of several solutions with a different 
number of clusters. In the second step, the initial cluster centres were used as non-random starting 
points in an iterative k-means clustering procedure. All analyses were performed with SPSS 18.0 
(SPSS Inc, Chicago, IL, USA).  
 
 
 
Results 
A total of 255 consecutive patients (mean age 57.4 ± 10 years, males 77%) referred to our centre 
between June 2004 and June 2006 for AFTCA have been enrolled. Patients with underlying 
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hypertrophic cardiomyopathy or moderate to severe valvular heart disease (n=67) were excluded. 
Arterial hypertension was reported in 127 (49.8%) patients, while previous episodes of congestive 
heart failure and known diagnosis of diabetes were reported in 17 (6.7%) and 14 (5.5%) patients, 
respectively. Baseline mean body mass index (BMI) was 26.4 ± 3.8. Twenty-nine (11.4%) patients 
presented a structural heart disease (ischaemic or dilated cardiomyopathy). Baseline clinical 
characteristics of the population are reported in Table 1.  
 
Long term freedom from arrhythmia recurrences 
Mean follow-up of the study population was 125 ± 7 months. No patients were lost at follow-up, 
while a redo procedure was performed in 111 (43%) patients; 20 (7.8%) patients died. Following 
over ten years, 27 (10.6%) patients progressed to permanent AF. Freedom from AF recurrences 
was 52% (Figure 1A), higher in patients with paroxysmal rather than persistent AF (61% vs. 44%, 
p=0.002, see Figure 2a). Freedom from AF after a single procedure was 32% (Figure 1B), higher 
within patients with paroxysmal rather than persistent AF (39% vs. 25%, p=0.001; Figure 2B). 
Between all patients free from arrhythmia recurrences at the end of follow up, including those 
undergone to redo procedures, 89 (66%) were free of antiarrhythmic drugs. In the remaining cases 
a class III antiarrhythmic drug was chosen in 20 (45%) of cases. Overall, however, prescription of 
of long term antiarrhythmic drug did not relate to a protective effect on recurrences (34% vs 49%, 
p 0.05). A subcutaneous long term monitoring system or definitive pacemaker implantation was 
reported in 48 (19%) patients during the follow up. 
At the univariate analysis, persistent AF (p=0.007), longer AF duration (p=0.003), presence of 
structural cardiomyopathy (p=0.018), increased antero-posterior left atrium diameter (p=0.013) 
and previous episodes of congestive heart failure (p=0.003) related to AF recurrences. On the other 
side, the absence of worsening during the follow up of arterial pressure (p=0.01), of fasting blood 
glucose (p=0.02),  and of BMI (p<0,001), together with an increase in the prescribed hypotensive 
therapy (p<0,001) related to a reduction of AF recurrences.  
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At multivariate Cox regression analysis, however, only a greater antero-posterior LA diameter  
was significantly related to recurrences (HR 1.05 95% CI 1.02-1.09 p=0.02) while an absence of 
increase in arterial pressure (HR 0.06 95% CI 0.02-0.20 p=0.01), of fasting blood glucose (HR 
0.58 95% CI 0.36-0.92 p=0.02) and of BMI (HR 0.06 95% CI 0.02-0.09 p<0.001) independently 
related to a reduction of AF recurrences (Table 2).  
Additionally, AF recurrences within patients stratified in two clusters, according to both BMI and 
arterial pressure control during the follow-up, are illustrated in Figure 3. Patients who observed a 
strict arterial pressure monitoring and did not increase baseline BMI showed a significantly higher 
freedom from recurrences compared to patients who did not at the end of follow-up (64% vs. 21%, 
p<0.001). 
 
Arrhythmic recurrence burden 
Among 109 patients with paroxysmal AF referred to our Centre for AFTCA, at the end of follow 
up 68 (62.4%) were free from arrhythmic recurrences. Between 41 patients who reported AF 
recurrences, 26 (23.9%) patients reported paroxysmal episodes of AF. On the other side, 10 (9.2%) 
patients presented an increased arrhythmic burden (persistent AF) and only a minority (5 patients, 
4.6%) of paroxysmal patients evolved to permanent AF. Among 146 persistent AF patients, at the 
end of follow-up 66 (45.2%) were free from AF recurrences. Among 80 (54.8%) patients who 
experienced AF recurrences, 21 (14.4%) patients showed the same arrhythmic burden (persistent 
AF) at the end of follow up, while progression to permanent AF was reported in 22 cases (15%). 
Focusing on patients referred for paroxysmal AFTCA, in whom paroxysmal AF was reported at 
the end of follow-up, a trend in arrhythmic burden reduction was observed; in fact, mean AF 
episodes number per year decreased from 152 to 30 at the end of follow-up, together with average 
episode duration from 250 to 100 min. 
 
Quality of life 
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A quality of life (QoL) score (SF36) has been proposed to each patient both at the time of AF 
ablation and during ambulatory visits at the end of follow-up. QoL test could not be performed at 
the end of follow up in deceased patients (n=20) and in other 7 cases who refused the test. As 
described in the Statistics section, a cluster analysis has been performed in order to evidence the 
QoL score variation according to baseline characteristics or arrhythmic burden. At the statistical 
analysis 3 different clusters have been identified considering mean score difference obtained in 
physical and mental performance compared to baseline. Clinical characteristics of different 
clusters have been analyzed in order to identify any clinical of pharmacological predictor of a 
better response in QoL following AFTCA. No baseline differences in terms of male/female 
patients prevalence were observed in the 3 cluster (p=0.67). Cluster 1 included patients who 
reported an increased value of QoL in both mental and physical performance. This subgroup of 
patients, compared to Cluster 2 patients characterized by reduction of both mental and physical 
performance, reported a higher rate of freedom from arrhythmic recurrences, a higher arrhythmic 
burden reduction and the higher prevalence of controlled cardiovascular risk factor (See Table 3 
and Figure 4). Cluster 3 patients reported a worsening of physical but an increasing in mental 
performance scores. Focusing on freedom from AF recurrences, arrhythmic burden reduction 
during follow-up, this Cluster presents an intermediate behaviour between the other two Clusters 
of patients. In the meantime, the increased mental performance is likely related to an arrhythmic 
burden reduction, that is similar to patients in Cluster 1 (See Table 3 for details).  
 
 
Thromboembolic and haemorrhagic events during follow up 
During follow-up 9 patients experienced a thromboembolic (TE) event (Table 4): an annual TE 
event rate of 0,3 per 100 patients year. All but one occurred during AF recurrences. The only 
patient who experienced a TE event during sinus rhythm was a hypertensive, 65 years old patient 
with a previous TE event before ablation. In three cases TE events occurred during AF recurrence 
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in patients not on oral anticoagulation. In one case a TE event lead to patient’s death. In two cases 
transient deficits occurred, and no other long term sequelae were reported. Seven haemorrhagic 
events occurred during follow-up, all in patients treated with oral anticoagulation with vitamin K 
antagonist, and only in one case an above therapeutic range (INR > 3) was reported. In one case 
surgical evacuation was required, one was treated by red blood cells transfusion, while in two 
cases, both traumatic, an intracranial haemorrhagic event lead to patients’ death. Overall, while 
three cases, as detailed above, were directly related to TE or haemorrhagic events, among the 20 
deceased patients, none was directly related to the ablation procedure. In 9 cases a terminal 
malignancy was reported as cause of death, while three patients died from heart failure. The cause 
of death was unknown in the remaining five patients.  
 
 
Discussion 
This is the first study reporting an over 10-years outcome of a large sample size of patients 
undergone to a standardized AFTCA approach in a single high volume centre focusing both on 
paroxysmal and persistent AF patients. Although several data are available concerning short and 
mid-term outcome, very long term outcome is at present reported only for paroxysmal AF patients 
undergone to AF ablation (7) or for patients undergone to surgical ablation (11).  
In general, progression of AF is common over time, as about 16% of patients with paroxysmal AF 
progress to permanent AF within one year, and this trend is only partially reduced by the 
subscription of antiarrhythmic drugs to about 7% per year (12). Conversely, this study suggests 
that a standardized approach for AFTCA limits this progression (13), although for selected 
patients, to about 1% per year. On top of classical parameters known to relate to recurrences, as an 
increased LA diameter, interestingly, risk factor control emerges as a new predictor of freedom 
from AF recurrences over 10-years follow-up.  
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More in details, the results of our study show the importance of periodical monitoring of patients 
undergone to AFTCA, because AF recurrences may occur also over long periods of follow-up, 
without reaching a plateau phase (4). Due to AF recurrences, at least one redo procedure was 
performed in 43.5% of patients, increasing significantly the freedom from AF recurrences from 
39% to 61% in paroxysmal and from 24% to 44% in persistent AF patients. In addition, despite 
34% of the patients free from recurrences at the end of follow up were still on antiarrhythmic 
therapy, when stratifying recurrences by the use or not of antiarrhythmic drugs, a not significant 
statistical trend emerges (p value 0.05) towards a lower prescription of AADs within subjects not 
experiencing arrhythmic recurrences, suggesting that long term antiarrhythmic therapy can be 
stopped within patients not experiencing recurrences. 
Long-term follow-up efficacy of AFTCA may be influenced by multiple factors. At univariate 
analysis, classical predictive factors related to AF recurrences played a role, such as baseline 
persistent AF (9), longer arrhythmia duration, increased left atrium diameter (15), presence of 
underlying cardiomyopathy or previous episode of congestive heart failure (11). At multivariate 
analysis, however, only a larger left atrium diameter maintained an independent predictive role for 
AF recurrences, likely reflecting its status of “marker” of an underlying atrial remodeling process, 
as well elucidated in previous studies (16). Interestingly, two clinical factors played a protective 
role on AF recurrences: patients with well managed blood pressure or BMI during follow-up 
reported a significantly higher arrhythmia free survival compared to those who did not (see Figure 
3). In addition, patients avoiding fasting blood glucose values increase experienced less relapses. 
In fact, recent research already reported the protective role on AF recurrences of a strict 
cardiovascular risk factor control both in patients undergone or not (17-18) to AFTCA. In fact, AF 
progression, driven by atrial fibrosis, has also been proved to relate to obesity (19). This is due to 
multiple remodeling factors, not only structural such as dilated left atrium or diastolic dysfunction, 
nor only functional, due to neuro-hormonal changes, but also electrical, because of a longer P 
wave duration due to inter-atrial conduction abnormalities. The role of increased blood pressure on 
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outcome of AFTCA has also been analyzed in previous studies, which showed the benefit of 
adequate blood pressure management on long-term freedom from AF recurrences (14).  
Eventually, our analysis on quality of life showed the benefit deriving from AF ablation in 
particular in Cluster 1 patients, in which the higher freedom from AF recurrences, the lower 
anticoagulant prescription rate and the higher arrhythmic burden reduction related with significant 
improvement of QoL over a more than 10-years period (Figure 4). Interestingly, also patients in 
Cluster 3 showed an increased mental score performance compared with baseline, even if the 
freedom from AF recurrences was not significantly different from patients in Cluster 2, but they 
showed an arrhythmic burden reduction analogue to Cluster 1 patients.  
Over a long-term follow-up, 9 TE events occurred with an overall incidence of 0.02 per 100 
patients year. Considering that the baseline CHA2DS2-VASc score of the population of 1.5 relates 
to an expected annual TE event rate between 1.3 and 2.2 per 100 patients years, the present study 
confirms the protective role of AF ablation on long term TE event occurrence (20). All 
haemorrhagic events occurred in patients on oral anticoagulation, and in one case an above 
therapeutic range INR was reported. According to these findings, in our opinion, a reasonable 
approach is to stop oral anticoagulation therapy only if a strategy of reliable continuous or daily 
heart rhythm analysis is available (e.g loop recorders, event recorders or similar). Only in this case 
the risk of a TE may be counterbalanced by the avoidable, known, haemorrhagic complication rate 
related to oral anticoagulation. 
 
Limitation 
First, this study shares all the weaknesses of observational, non-randomized studies. Hopefully 
that all the procedures were performed in a single high volume centre with a standardized AFTCA 
approach should mitigate this limitation. Second, the absence of standardized invasive ECG 
monitoring, that cannot be considered as a common approach, could potentially have missed some 
asymptomatic arrhythmia recurrences not occurring during a 24 hours Holter ECG performed. On 
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the other side subcutaneous long term monitoring system or definitive pacemaker implantation 
was reported in 19% of cases and patients were instructed to daily pulse detection and, when not 
able, they were recently invited to use a blood pressure device able to detect irregular heart-beat. 
Third, technology improvements both for electroanatomic mapping systems and for catheter 
design, moreover the physicians’ learning curve, due to the nature of an observational study, 
cannot be assessed. Last, the heterogeneity among each different predictive value, such as BMI, 
hypertension or fasting blood glucose average, in this observational study, was not standardly 
assessed. 
 
 
 
 
Conclusion 
Over 10-years outcome of AF ablation in selected patients treated with a standardized AFTCA 
approach is characterized by a limited incidence of progression towards permanent AF. 
Performing repeated procedures and optimal management of cardio-metabolic risk factor are of 
paramount importance in preventing arrhythmic recurrences. Very long term quality of life relates 
not only to freedom from AF recurrences, but also to arrhythmic burden reduction. TE and 
haemorrhagic complications during follow-up, additionally, are lower than expected in a 
comparable AF population. 
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Figure legends 
Figure 1. Kaplan Meier estimate of long-term AF-free survival including 111 (43%) redo 
procedures (A) and after a single procedure (B). 
 
Figure 2. Kaplan Meier estimate of long-term AF-free survival including 111 (43%) redo 
procedures (A) and after a single procedure (B) in patients with paroxysmal and persistent atrial 
fibrillation. 
 
Figure 3. Kaplan-Meier estimate of arrhythmia-free survival according to optimal or poor blood 
pressure and BMI control during follow-up. 
 
Figure 4. Quality of life change during follow-up assessed by SF38 score according to 3 Clusters. 
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Table 1. Baseline characteristics of the included patients. IQR: interquartile range; BMI: body mass 
index; AF: atrial fibrillation; LA: left atrial; TIA: transient ischemic attack; OAT: oral anticoagulant 
treatment. 
 Baseline Characteristics (n = 255)  
Age at inclusion, years [IQR] 58 [IQ 51-65] 
Male sex, n (%) 197 (77.2) 
Hypertension, n (%) 127 (49.8) 
Mean systolic blood pressure, mmHg [IQR] 125 [120-130] 
Mean diastolic blood pressure, mmHg [IQR] 80 [75-82] 
Congestive heart failure, n (%) 17 (6.7) 
Diabetes, n (%) 14 (5.5) 
Fasting blood glucose, mg/dl [IQR]  92 [IQ 88-98] 93.1 ± 12.7 
BMI, Kg/m2 [IQR] 25.4 [23.9-28.0] 
Dysthyroidism, n (%) 52 (20.4) 
Dyslipidaemia, n (%) 59 (23.1) 
Gastrointestinal disease, n (%) 31 (12.2) 
History of atrial fibrillation, months [IQR] 35 [IQ 13-73] 
Paroxysmal AF, n (%) 109 (42.7) 
Persistent AF, n (%) 146 (57.2) 
Structural heart disease, n (%) 29 (11.4) 
Left ventricular ejection fraction, % [IQR] 60 [IQ 55- 62] 58.7 ± 7.1 
LA antero-posterior diameter, mm [IQR] 46 [IQ 42-51] 
Prior stroke/TIA, n (%) 29 (11.4) 
CHA2DS2-VASc score   
 19 
0, n (%) 73 (28.6) 
1, n (%) 81 (31.8) 
≥2, n (%)  101 (39.6) 
Medical therapy   
IC drugs, n (%) 86 (33.7) 
III class, n (%) 107 (41.9) 
OAT, n (%) 103 (40.4) 
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Table 2. Univariate and multivariate analysis of baseline characteristics related to AF recurrence 
during follow-up. AF: atrial fibrillation; IQR: interquartile range; NS: non significant; BMI: body 
mass index; LA: left atrial; LV: left ventricular; BP: blood pressure. 
Univariate and multivariate predictors of AF recurrence 
 
NO 
RECURRENCE 
after last 
procedure 
RECURRENCE 
after last 
procedure 
P-value 
(univariate) 
P-value 
(multivariate) 
Hazard Ratio   
[95% C.I.] 
N 134 121    
Paroxysmal AF, n (%) 68 (50.7) 41 (33.9) 0.007 0.99 1.00 
[0.62-1.6] 
AF duration, months [IQR] 31 [IQ 12 – 67] 42 [IQ 19 – 93] 0.003 0.25 1.00 
[0.99-1.005] 
Cardiomyopathy, n (%) 16 (11.9) 28 (23) 0.018 0.56 1.14 
[0.73-1.81] 
LV ejection fraction, % 
[IQR] 
58.6 ± 6.9 58.3 ± 7.4 0.69 NS NA 
LA antero-posterior 
diameter, mm [IQR] 
44.8 ± 6 47.1 ± 5.7 0.013 0.02 1.05 
[1.02-1.09] 
Hypertension, n (%) 62 (46.3) 65 (53.7) 0.23 NS NA 
No BP worsening at follow-
up, n (%) 
82 (61.2) 24 (19.8) < 0.001 0.01 0.06 
[0.02-0.20] 
Increased hypotensive 
therapy, n (%) 
65 (48.5) 35 (28.9) <0.001 <0.001 0.06 
[0.02-0.18] 
Diabetes, n (%) 5 (3.7) 9 (7.4) 0.19 NS NA 
No blood glucose worsening 
at follow up, n (%) 
72 (53.7) 47 (38.8) 0.017 0.023 0.58 
[0.36-0.92] 
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Congestive heart failure, n 
(%) 
3 (2.2) 14 (11.6) 0.003 0.95 1.02 
[0.51-2.07] 
No BMI worsening, n (%) 74 (55.2) 24 (19.8) <0.001 <0.001 0.06 
[0.02-0.09] 
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Table 3. Quality of life variation during follow-up. The analysis did not include 20 patients 
deceased during follow-up and 7 patients that refused to complete the quality of life questionnaire.  
AF: atrial fibrillation; BMI: body mass index; BP: blood pressure. 
 
Change in quality of life at follow-up (n=227) 
 Cluster 1 Cluster 2 Cluster 3 P-value  
N 88 100 39  
Male Sex, n (%) 77 (87) a 84 (84) a 32 (82) a 0.67 
AF recurrence following last 
procedure, n (%) 
29 (33) a 64 (64) b 18 (46) a,b <0.001 
Persistent or permanent AF at 
follow up, n (%) 
10 (11) a 36 (36) b 8 (20) a,b <0.001 
No BMI or BP worsening at 
follow-up, n (%) 
26 (29) a 15 (15) b 11 (28) a,b 0.042 
Reduced arrhythmic burden at 
follow up, n (%) 
85 (96) a  41 (41) b 35 (89) a <0.001 
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Table 4. Thromboembolic and haemorrhagic events during follow-up (OAT: oral anticoagulant treatment; INR: international normalized ratio; AF: 
atrial fibrillation; SR: sinus rhythm; GE: gastroenterological) 
Patient 
n° 
Age 
(y/o) 
Time 
from 
ablation 
(months) 
CHA2D
S2-Vasc 
score 
HAS-
BLED 
score 
Rhythm OAT INR 
If not on OAT, 
months from 
suspension 
Sequelae  
Thromboembolic events (stroke/TIA) 
1 59 32 1 0 AF No - 1 None 
2 75 59 3 1 AF No - 56 None 
3 55 80 2 1 AF No - 60 None 
4 59 124 1 1 AF Yes In range - None 
5 43 6 3 1 AF Yes In range - None 
6 73 113 1 1 AF Yes In range - Transient deficit 
7 65 93 4 2 SR Yes In range - None 
 24 
8 77 19 7 4 AF Yes In range - Deceased 
9 80 65 4 2 AF Yes In range - Transient deficit 
Major Haemorrhagic events 
10 50 19 2 1 SR Yes In range - None (Gynaecological bleeding) 
11 57 99 0 0 AF Yes In range - None (GI bleeding) 
12 74 105 3 1 AF Yes In range  None (Retinal bleeding) 
13 76 128 3 2 AF Yes Above 3 - Surgical treatment (intracapsular 
knee joint haemorrhage) 
14 63 81 1 0 SR Yes In range - Transfusion (GI bleeding) 
15 
48 79 2  1 AF Yes 
In range - Deceased (Subdural hematoma, 
traumatic) 
9 
81 67 6 3 AF Yes 
In range - Deceased (Intracranial bleeding, 
traumatic) 
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Figure 1. 
 
 
 
 
 26 
Figure 2. 
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Figure 3.          Figure 4. 
 
 
 
